Literature DB >> 17195849

Selective inhibitors of death in mutant huntingtin cells.

Hemant Varma1, Cindy Voisine, C Todd DeMarco, Elena Cattaneo, Donald C Lo, Anne C Hart, Brent R Stockwell.   

Abstract

Huntington disease (HD) is an inherited neurodegenerative disorder with unclear pathophysiology. We developed a high-throughput assay in a neuronal cell culture model of HD, screened 43,685 compounds and identified 29 novel selective inhibitors of cell death in mutant huntingtin-expressing cells. Four compounds were active in diverse HD models, which suggests a role for cell death in HD; these compounds are mechanistic probes and potential drug leads for HD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17195849     DOI: 10.1038/nchembio852

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  16 in total

1.  Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease.

Authors:  Steven P Braithwaite; Ralf S Schmid; Dong Ning He; Mei-Li A Sung; Seongeon Cho; Lynn Resnick; Michael M Monaghan; Warren D Hirst; Christian Essrich; Peter H Reinhart; Donald C Lo
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

Review 2.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

3.  Inhibitors of metabolism rescue cell death in Huntington's disease models.

Authors:  Hemant Varma; Richard Cheng; Cindy Voisine; Anne C Hart; Brent R Stockwell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 4.  Neurobiological applications of small molecule screening.

Authors:  Andras Bauer; Brent Stockwell
Journal:  Chem Rev       Date:  2008-05-01       Impact factor: 60.622

5.  Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity.

Authors:  Salvatore La Rosa; Tiziana Benicchi; Laura Bettinetti; Ilaria Ceccarelli; Enrica Diodato; Cesare Federico; Pasquale Fiengo; Davide Franceschini; Ozgun Gokce; Freddy Heitz; Giulia Lazzeroni; Ruth Luthi-Carter; Letizia Magnoni; Vincenzo Miragliotta; Carla Scali; Michela Valacchi
Journal:  ACS Med Chem Lett       Date:  2013-08-08       Impact factor: 4.345

6.  CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease.

Authors:  Jill R Crittenden; Denise E Dunn; Farhan I Merali; Ben Woodman; Michael Yim; Anna E Borkowska; Matthew P Frosch; Gillian P Bates; David E Housman; Donald C Lo; Ann M Graybiel
Journal:  Hum Mol Genet       Date:  2010-02-10       Impact factor: 6.150

7.  Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay.

Authors:  Peter H Reinhart; Linda S Kaltenbach; Christian Essrich; Denise E Dunn; Joshua A Eudailey; C Todd DeMarco; Gregory J Turmel; Jennifer C Whaley; Andrew Wood; Seongeun Cho; Donald C Lo
Journal:  Neurobiol Dis       Date:  2011-03-31       Impact factor: 5.996

Review 8.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

9.  Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway.

Authors:  Hemant Varma; Ai Yamamoto; Melissa R Sarantos; Robert E Hughes; Brent R Stockwell
Journal:  J Biol Chem       Date:  2010-09-21       Impact factor: 5.157

10.  Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.

Authors:  Wan Seok Yang; Brent R Stockwell
Journal:  Chem Biol       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.